SomaLogic and Korea’s DNA Link have joined forces to introduce the groundbreaking 7,000-Plex SomaScan platform to the rapidly expanding Asia-Pacific proteomics market. This innovative technology, known as the SomaScan Proteomics Assay, has the remarkable capability of simultaneously measuring 7,000 proteins, making it an invaluable asset for DNA research.
To further enhance their proteomics offerings, SomaLogic has entered into a strategic partnership with Illumina. Together, they are collaborating on the development of co-exclusive, co-branded, next-generation sequencing (NGS)-based proteomics products. This collaboration is set to revolutionize the field of proteomics and drive significant advancements in DNA research.
The proteomics market is projected to experience substantial growth, with a high compound annual growth rate (CAGR) of 13.5% from 2022 to 2032. By 2032, it is estimated that the market will reach an impressive value of US$ 109,485.7 Million. This exponential growth is fueled by the increasing awareness of the wide-ranging applications of proteomics in various fields.
In addition to their partnership with DNA Link, SomaLogic has also teamed up with Dante Genomics to provide top-notch proteomics services in the European market. This strategic collaboration allows SomaLogic to expand its reach and cater to the growing demand for advanced proteomics solutions in Europe.
The growing recognition of the immense potential of proteomics is expected to be a major driver for market growth. It is anticipated that by 2032, the proteomics market will reach a staggering value of USD 65.2 billion. This signifies the increasing adoption of proteomics technologies and their pivotal role in advancing scientific research and medical diagnostics.
Overall, with these strategic partnerships and the rising prominence of proteomics, SomaLogic is well-positioned to lead the way in revolutionizing the field and shaping the future of DNA research.
SomaLogic, Inc.
SLGC
Neutral
Updated on: 19/09/2023
Financial Health
Weak
Debt to equity ratio: Neutral
Price to earnings ratio: Sell
Price to book ratio: Buy
DCF: Strong Buy
ROE: Sell
SLGC Stock Performance on September 19, 2023: Mixed Results and Challenging Financial Performance
SLGC Stock Performance on September 19, 2023
SLGC, a company in the Commercial Services sector, had a mixed performance on September 19, 2023, according to data from CNN Money. The stock opened at $2.29, slightly higher than the previous close of $2.28. Throughout the day, the stock fluctuated within a range of $2.23 to $2.31. The trading volume for the day was 39,871 shares, significantly lower than the average volume of 996,288 shares over the past three months. The market capitalization of SLGC stood at $438.2 million.
SLGC’s financial performance has been challenging in recent times. The company experienced a decline in earnings growth of -23.04% last year and a further decline of -2.12% this year. However, no data is available for the earnings growth projection for the next five years. On the other hand, the company witnessed a positive revenue growth of 19.65% last year.
When considering valuation metrics, SLGC has a price/sales ratio of 4.73 and a price/book ratio of 0.78. The price/earnings (P/E) ratio is not available, indicating that the company may not have positive earnings. The net profit margin for SLGC is -111.77%, indicating that the company is currently operating at a loss.
Looking ahead, SLGC’s next reporting date is scheduled for November 13, 2023. Analysts forecast an earnings per share (EPS) of -$0.13 for this quarter. In the previous fiscal year, SLGC reported annual revenue of $97.7 million but suffered a net loss of -$109.2 million.
Despite the challenging financial performance, SLGC continues to operate in the Miscellaneous Commercial Services industry. The company’s corporate headquarters are not disclosed.
Investors and analysts will closely monitor SLGC’s upcoming financial reports to assess the company’s progress and potential for improvement.
Somalogic Incs Stock Performance and Analyst Consensus: Potential 160.87% Increase in 12 Months
On September 19, 2023, Somalogic Inc’s (SLGC) stock performance was closely watched by investors. According to data from CNN Money, four analysts have provided 12-month price forecasts for SLGC, with a median target of $6.00. The high estimate stands at $7.00, while the low estimate is $3.50. This indicates a potential increase of 160.87% from the last recorded price of $2.30.
The consensus among the four polled investment analysts is to buy stock in Somalogic Inc. This rating has remained unchanged since January, indicating a consistent positive sentiment towards the company’s prospects.
Discussion about this post